R&D/Clinical Trials

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

AlzeCure Pharma has licensed its NeuroRestore platform and lead CNS candidate ACD856 to QuantumCell ApS, following positive Phase Ib safety and pharmacokinetic data.

New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable.

FDA plans a pilot to shorten early-stage drug trial timelines, raising strategic questions for biopharma development and investment.

Biogen has agreed to acquire private immunology biotech RayThera for up to $1 billion, adding a suite of undisclosed small molecule anti-inflammatory candidates to its pipeline.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

Protillion Biosciences and AbCellera each secured platform-based drug discovery deals this week, with Protillion partnering with Merck on multi-target protein engineering in a deal worth up to $510 million and Jazz Pharmaceuticals committing up to $84 million upfront to AbCellera for T-cell engaging multispecific antibodies in gastrointestinal cancers.

5 Prime Sciences CEO discusses how simply building a massive data set can cause more problems than it solves during clinical trials.

Elicio Therapeutics' KRAS-targeting immunotherapy ELI-002 7P missed its primary endpoint in a Phase II adjuvant pancreatic cancer trial, sending shares down 47%.

Polaryx’s chief medical officer discusses the regulatory environment for rare, pediatric treatments and how it’s directly impacting clinical trials.

The two executives discuss joining Persica Pharmaceuticals and how they’re driving the company forward with non-opioid pain medication.

With clinical trial data exploding to nearly 6 million datapoints, eClinical Solutions' CEO and Co-founder, Raj Indupuri makes the case for price transparency and a measurable ROI in clinical data technology.

Jazz Pharmaceuticals' Zepzelca failed to improve overall survival in the Phase III Lagoon confirmatory trial for second-line small cell lung cancer, putting its accelerated approval in that setting at risk.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

How emerging investment models are rewiring biotech funding structures for efforts in rare disease.

Lisa Bollinger, chief medical officer at Polaryx, discusses signs that regulatory agencies are taking the issues related to rare disease therapy development seriously.

In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory and reimbursement pressure, and embed technology into the operational infrastructure of care delivery.

Over the past decade, PRCCI has helped bring more than 300 clinical trial opportunities to Puerto Rico, supported over 90 clinical research contracts, and collaborated with more than 116 physicians and investigators across the Island.

With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.

State-level access pathways won't cannibalize clinical trials for patients. Instead they could solve biotech's in-human data catch-22, and restore patient trust along the way.

Incyte, Galmed Pharmaceuticals, and Johnson & Johnson each announced acquisitions this week, with deals spanning a $2 billion bet on a Phase III bleeding disorder antibody, a GI medtech pivot, and a $1 billion move into KRAS-targeting degrader conjugates as dealmaking across therapeutic categories continues.

Roche has struck an exclusive collaboration with Nurix Therapeutics to co-develop BTK degrader bexobrutideg, paying over $700 million upfront in a deal that could top $3 billion in total.

Driven by rising prevalence and awareness of aesthetic appeal and self-image, the Alopecia Areata market is poised for steady growth.

Amidst this backdrop of challenges, one area of promise for closing gaps and advancing ovarian cancer care is the growing availability of high-quality, research-ready, real-world data.

Robertson discusses the trends shaping the future of oncology commercialization.